JP2025504476A5 - - Google Patents
Info
- Publication number
- JP2025504476A5 JP2025504476A5 JP2024543135A JP2024543135A JP2025504476A5 JP 2025504476 A5 JP2025504476 A5 JP 2025504476A5 JP 2024543135 A JP2024543135 A JP 2024543135A JP 2024543135 A JP2024543135 A JP 2024543135A JP 2025504476 A5 JP2025504476 A5 JP 2025504476A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- rna
- composition according
- guide
- guide rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301033P | 2022-01-19 | 2022-01-19 | |
| US63/301,033 | 2022-01-19 | ||
| US202263303479P | 2022-01-26 | 2022-01-26 | |
| US63303479 | 2022-01-26 | ||
| US202263390222P | 2022-07-18 | 2022-07-18 | |
| US63/390,222 | 2022-07-18 | ||
| PCT/US2023/060939 WO2023141531A2 (en) | 2022-01-19 | 2023-01-19 | Transmembrane receptor gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504476A JP2025504476A (ja) | 2025-02-12 |
| JP2025504476A5 true JP2025504476A5 (enExample) | 2026-01-27 |
Family
ID=87349166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543135A Pending JP2025504476A (ja) | 2022-01-19 | 2023-01-19 | 膜貫通受容体遺伝子編集 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4466345A4 (enExample) |
| JP (1) | JP2025504476A (enExample) |
| KR (1) | KR20240137036A (enExample) |
| CN (1) | CN119053696A (enExample) |
| AU (1) | AU2023210278A1 (enExample) |
| CA (1) | CA3243087A1 (enExample) |
| IL (1) | IL314281A (enExample) |
| WO (1) | WO2023141531A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026085500A1 (en) * | 2024-10-17 | 2026-04-23 | Orthobio Therapeutics, Inc. | Transmembrane receptor gene editing |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102083973A (zh) * | 2008-01-21 | 2011-06-01 | 国立大学法人东京农工大学 | 新型真菌病毒、植物病害真菌减毒菌株、植物病害防治剂、真菌病毒的生产方法、植物病害真菌减毒的方法以及植物病害的防治方法 |
| WO2016081924A1 (en) * | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
| US10954513B2 (en) * | 2015-06-18 | 2021-03-23 | University Of Utah Research Foundation | RNA-guided transcriptional regulation and methods of using the same for the treatment of back pain |
| US11471462B2 (en) * | 2016-06-27 | 2022-10-18 | The Broad Institute, Inc. | Compositions and methods for detecting and treating diabetes |
| WO2019076651A1 (en) * | 2017-10-17 | 2019-04-25 | Universität Heidelberg | MODULATED CASE INHIBITORS |
| CA3103031A1 (en) * | 2018-06-18 | 2019-12-26 | Universite Laval | Methods and tools for plant pathogen assessment |
| WO2020081922A1 (en) * | 2018-10-18 | 2020-04-23 | University Of Utah Research Foundation | Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain |
| JP7642548B2 (ja) * | 2019-02-01 | 2025-03-10 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| AU2020304057A1 (en) * | 2019-06-27 | 2022-01-27 | Benaroya Research Institute At Virginia Mason | Artificial antigen-specific immunoregulatory t (airt) cells |
| CN110747211A (zh) * | 2019-10-31 | 2020-02-04 | 北京兴元和济生命医学科技有限公司 | 基于crispr的改变基因产物表达的方法及其应用 |
-
2023
- 2023-01-19 EP EP23743926.0A patent/EP4466345A4/en active Pending
- 2023-01-19 WO PCT/US2023/060939 patent/WO2023141531A2/en not_active Ceased
- 2023-01-19 IL IL314281A patent/IL314281A/en unknown
- 2023-01-19 KR KR1020247027380A patent/KR20240137036A/ko active Pending
- 2023-01-19 CN CN202380027932.2A patent/CN119053696A/zh active Pending
- 2023-01-19 JP JP2024543135A patent/JP2025504476A/ja active Pending
- 2023-01-19 CA CA3243087A patent/CA3243087A1/en active Pending
- 2023-01-19 AU AU2023210278A patent/AU2023210278A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Merkel et al. | Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance | |
| US12350383B2 (en) | Cationic lipids containing silicon | |
| JP2022506956A5 (enExample) | ||
| JP2021526804A5 (enExample) | ||
| CA3118559A1 (en) | Lipid nanoparticle formulations | |
| JP2022502055A5 (enExample) | ||
| RU2699706C2 (ru) | Вещества и способы модуляции заживления сухожилий | |
| Teo et al. | Macrophage polarization as a facile strategy to enhance efficacy of macrophage membrane‐coated nanoparticles in osteoarthritis | |
| CN107001627A (zh) | 用于将核酸引入细胞的组合物 | |
| US11987791B2 (en) | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression | |
| CN108472354A (zh) | 呼吸道合胞病毒疫苗 | |
| JP2019529489A5 (enExample) | ||
| CN115697321A (zh) | 用于向肝星状细胞递送治疗剂的脂质纳米颗粒的阳离子脂质 | |
| Wang et al. | Tetrahedral framework nuclear acids can regulate interleukin-17 pathway to alleviate inflammation and inhibit heterotopic ossification in ankylosing spondylitis | |
| KR20250071293A (ko) | 유전자 편집 시스템을 위한 지질 나노입자 | |
| WO2024026257A2 (en) | Engineered polynucleotides for cell selective expression | |
| JP2019509034A5 (enExample) | ||
| CN118695849A (zh) | 用于向施万细胞的靶向递送的设计者细胞外囊泡 | |
| TWI884297B (zh) | mRNA奈米膠囊及其用於製備抗病毒藥物的用途 | |
| CN102406653B (zh) | 一种miRNA的抗病毒作用、实施方法及用途 | |
| Bao et al. | Transcriptome profiling of the subventricular zone and dentate gyrus in an animal model of Parkinson's disease | |
| JP2023509101A (ja) | 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物 | |
| US20170348393A1 (en) | Treatment of cns inflammatory disorders | |
| JP2021524735A (ja) | ヘキサマー４面体ｒｎａナノ構造 | |
| CN119998457A (zh) | 基于金属纳米颗粒-核酸缀合物的基因载体 |